Lacosamide in refractory mixed pediatric epilepsy: a prospective add-on study.

Abstract

Lacosamide is a new antiepileptic drug that is currently approved by the US Food and Drug Administration (FDA) for adults 17 years or older for partial-onset seizures. The authors reviewed 21 pediatric patients (<17 years) with various seizure types who were started on oral lacosamide as part of a prospective add-on study as adjunctive therapy for refractory epilepsy. Five patients were excluded due to less than 3 months of meaningful follow-up. Maintenance dosages used ranged from 2.4 to 19.4 mg/kg/d. Eight of 16 (50%) patients had greater than 50% reduction in seizure frequency with adjunctive lacosamide therapy. Eight (50%) patients had generalized epilepsy including 4 with Lennox-Gastaut syndrome. Lacosamide was effective therapy for most seizure types but was particularly effective for partial-onset seizures. Lacosamide was effective in treating 5 of 8 (62.5%) localization-related epilepsies but only 2 of 8 (25%) generalized epilepsies, both Lennox-Gastaut syndrome patients with greater than 90% seizure reduction. None of these very refractory patients remained seizure free.

• Authors: Reena Gogia Rastogi, Yu-Tze Ng
• Journal: Journal of child neurology (J Child Neurol) Vol. 27 Issue 4 Pg. 492-5 (Apr 2012) ISSN: 1708-8283 [Electronic] United States
• PMID: 22467791 (Publication Type: Journal Article)

Chemical References

• Acetamides
• Anticonvulsants
• Lacosamide

Topics

• Acetamides (therapeutic use)
• Adolescent
• Anticonvulsants (therapeutic use)
• Child
• Child, Preschool
• Diet, Ketogenic (methods)
• Epilepsy (classification, diet therapy, drug therapy)
• Female
• Humans
• Infant
• Lacosamide
• Male
• Pediatrics
• Prospective Studies
• Treatment Outcome
• Vagus Nerve Stimulation (methods)